Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 311Leukemia, Lymphocytic, Chronic, B-Cell 108Myelodysplastic Syndromes 63Recurrence 55Leukemia 43Neoplasms 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Lymphoma, Non-Hodgkin 41Lymphoma, Mantle-Cell 32Multiple Myeloma 28Lymphoma, Large B-Cell, Diffuse 27Leukemia, Myelomonocytic, Chronic 27Lymphoma, Follicular 22Lymphoma 21Hematologic Neoplasms 20Lymphoma, B-Cell, Marginal Zone 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Burkitt Lymphoma 16Myeloproliferative Disorders 11Lymphoma, B-Cell 11Leukemia, Myeloid 11Neoplasm, Residual 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Waldenstrom Macroglobulinemia 9Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Chromosome 17 deletion 6Leukemia, B-Cell 5Immunoglobulin Light-chain Amyloidosis 5Breast Neoplasms 5

Interventions

Dexamethasone 111Cyclophosphamide 99Melphalan 91Bortezomib 69Peripheral Blood Stem Cell Transplantation 64Lenalidomide 58fludarabine phosphate 56Busulfan 54Filgrastim 50Tacrolimus 38Antilymphocyte Serum 38Thalidomide 36Radiotherapy 36Mycophenolic Acid 33fludarabine 28Cyclosporine 26Methotrexate 25Etoposide 22Calcium Dobesilate 22Whole-Body Irradiation 21Prednisone 21Methylprednisolone 20sargramostim 19pomalidomide 19Granulocyte Colony-Stimulating Factor 18carfilzomib 16daratumumab 15Cord Blood Stem Cell Transplantation 15Carmustine 14Rituximab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms, Plasma Cell × venetoclax × Clear all
NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

AbbVie

Phase 2 Active not recruiting
120 enrolled
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Pfizer

Phase 1 Terminated
189 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡